<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0407233845
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        EVOX 750MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LEVOFLOXACIN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        750
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        7
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        60.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Jordan Sweden Medical and Sterilization Co." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 679]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-DAWAA MEDICAL SERVICES CO. LTD
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Jordan Sweden Medical and Sterilization Co.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01MA12
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT EVOX (LEVOFLOXACIN)?<br />Evox (Levofloxacin), a fluoroquinolone antibiotic, can cause serious side effects. Some of these serious<br />side effects could result in death.<br />If you have any of the following serious side effects while you take Evox, get medical help right away. Talk with<br />your healthcare provider about whether you should continue to take Evox.<br />1. Tendon rupture or swelling of the tendon (tendinitis).<br />&bull; Tendon problems can happen in people of all ages who take Levofloxacin. Tendons are tough cords of<br />tissue that connect muscles to bones.<br />Some tendon problems include pain, swelling, tears, and inflammation of tendons including the back of the ankle<br />(Achilles), shoulder, hand, or other tendon sites.<br />&bull; The risk of getting tendon problems while you take Levofloxacin is higher if you:<br />- are over 60 years of age<br />- are taking steroids (corticosteroids)<br />- have had a kidney, heart or lung transplant.<br />&bull; Tendon problems can happen in people who do not have the above risk factors when they take Levofloxacin.<br />&bull; Other reasons that can increase your risk of tendon problems can include:<br />- physical activity or exercise<br />- kidney failure<br />- tendon problems in the past, such as in people with rheumatoid arthritis (RA)<br />Call your healthcare provider right away at the first sign of tendon pain, swelling or inflammation. Stop taking<br />Levofloxacin until tendinitis or tendon rupture has been ruled out by your healthcare provider. Avoid exercise and<br />using the affected area.<br />The most common area of pain and swelling is the Achilles tendon at the back of your ankle. This can also happen<br />with other tendons. Talk to your healthcare provider about the risk of tendon rupture with continued use of<br />Levofloxacin. You may need a different antibiotic that is not a fluoroquinolone to treat your infection.<br />&bull; Tendon rupture can happen while you are taking or after you have finished taking Levofloxacin. Tendon ruptures<br />have happened up to several months after people have finished taking their fluoroquinolone.<br />&bull; Get medical help right away if you get any of the following signs or symptoms of a tendon rupture:<br />- hear or feel a snap or pop in a tendon area<br />- bruising right after an injury in a tendon area<br />- unable to move the affected area or bear weight<br />2. Worsening of myasthenia gravis (a problem that causes muscle weakness). Fluoroquinolones like<br />Levofloxacin may cause worsening of myasthenia gravis symptoms, including muscle weakness and breathing<br />problems. Call your healthcare provider right away if you have any worsening muscle weakness or breathing<br />problems.<br />&bull; See &ldquo;What are the possible side effects of Levofloxacin?&rdquo;</p><p>&nbsp;</p><p>Evox (Levofloxacin) is a fluoroquinolone antibiotic medicine used in adults&rsquo; age 18 years or older to treat certain<br />infections caused by certain germs called bacteria. These bacterial infections include:<br />&bull; Sinuses.<br />&bull; Lungs, in people with long-term breathing problems or pneumonia.<br />&bull; Urinary tract, including your kidneys or bladder.<br />&bull; Prostate gland, where you have a long lasting infection.<br />&bull; Skin and underneath the skin, including muscles. this is sometimes called &ldquo;soft tissue&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Levofloxacin if you have ever had a severe allergic reaction to an antibiotic known as a fluoroquinolone, or if you are allergic to levofloxacin.</p><p><strong>Before you take Levofloxacin, tell your healthcare provider if you:</strong><br />&bull; have tendon problems.<br />&bull; have a problem that causes muscle weakness (myasthenia gravis).<br />&bull; have central nervous system problems such as seizures (epilepsy).<br />&bull; have nerve problems.<br />&bull; have or anyone in your family has an irregular heartbeat, especially a condition called &ldquo;QT prolongation&rdquo;.<br />&bull; have low blood potassium (hypokalemia).<br />&bull; have bone problems.<br />&bull; have joint problems including rheumatoid arthritis (RA).<br />&bull; have kidney problems. You may need a lower dose of Levofloxacin if your kidneys do not work well.<br />&bull; have liver problems.<br />&bull; have diabetes or problems with low blood sugar (hypoglycemia).<br />&bull; are pregnant or plan to become pregnant. It is not known if levofloxacin will harm your unborn child.<br />&bull; are breastfeeding or plan to breastfeed. It is not known if Levofloxacin passes into your breast milk. You and your healthcare provider should decide if you will take Levofloxacin or breastfeed. You should not do both.<br />&bull; have been diagnosed with an enlargement or &quot;bulge&quot; of a large blood vessel (aortic aneurysm or large vessel peripheral aneurysm).<br />&bull; have experienced a previous episode of aortic dissection (a tear in the aorta wall).<br />&bull; have a family history of aortic aneurysm or aortic dissection or other risk factors or predisposing conditions (e.g. connective tissue disorders such as Marfan syndrome, or vascular Ehlers-Danlos syndrome, or vascular disorders such as Takayasu arteritis, giant cell arteritis, Behcet&#39;s disease, high blood pressure, or known atherosclerosis).<br />If you feel sudden, severe pain in your abdomen, chest or back, go immediately to an emergency room.<br /><strong>Tell your healthcare provider about all the medicines you take, including prescription and non-prescription&nbsp;medicines, vitamins, and herbal supplements.</strong><br />Levofloxacin and other medicines can affect each other causing side effects.<br />Especially tell your healthcare provider if you take:<br />&bull; a steroid medicine.<br />&bull; an anti-psychotic medicine.<br />&bull; a tricyclic antidepressant.<br />&bull; a water pill (diuretic).<br />&bull; certain medicines may keep Levofloxacin from working correctly. Take Levofloxacin Tablets either 2 hours before<br />or 2 hours after taking these medicines or supplements:<br />- an antacid, multivitamin, or other medicines or supplements that have magnesium, aluminum, iron, or zinc.<br />- sucralfate.<br />- didanosine.<br />&bull; a blood thinner (Warfarin, Coumadin, Jantoven).<br />&bull; an oral anti-diabetes medicine or insulin.<br />&bull; an NSAID (Non-Steroidal Anti-Inflammatory Drug). Many common medicines for pain relief are NSAIDs. Taking an NSAID while you take Levofloxacin or other fluoroquinolones may increase your risk of central nervous system effects and seizures.<br />&bull; theophylline.<br />&bull; a medicine to control your heart rate or rhythm (antiarrhythmics).<br />Ask your healthcare provider if you are not sure if any of your medicines are listed above.<br />Know the medicines you take. Keep a list of your medicines and show it to your healthcare provider and pharmacist when you get a new medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Take Evox exactly as your healthcare provider tells you to take it.<br />&bull; Take this medicine by mouth.<br />&bull; Swallow the tablets whole with a drink of water<br />&bull; Take Evox at about the same time each day.<br />&bull; Evox Tablets can be taken with or without food.</p><p><strong>HOW MUCH TO TAKE:</strong><br />&bull; Your doctor will decide on how many tablets you should take.<br />&bull; The dose will depend on the type of infection you have and where the infection is in your body<br />&bull; the length of your treatment will depend on how serious your infection is.<br />&bull; if you feel the effect of your medicine is too weak or strong, do not change the dose yourself, but ask your doctor.<br />&bull; The scoring line on Evox 250 and 500 is for differentiation only and the tablet cannot be break into two halfs.<br />&bull; Adults and the elderly.<br /><strong>Dosage for Evox 250 and 500 mg</strong><br />- Sinuses: Two tablets of Evox 250 mg, once each day or one tablet of Evox 500 mg once each day.<br />- Lungs, in people with long-term breathing problems: One or two tablets of Evox 250 mg, once each day or one tablet of Evox 500 mg once each day.<br />- Pneumonia: Two tablets of Evox 250 mg once or twice each day, or one tablet of Evox 500 mg once or twice each day.<br />- Urinary tract, including your kidneys or bladder: One tablet of Evox 250 mg each day.<br />- Prostate gland: Two tablets of Evox 250 mg once each day. Or one tablet of Evox 500 mg once each day.<br />- Skin and underneath the skin, including muscles: One or two of tablets of Evox 250 mg once or twice each day or one tablet of Evox 500 mg once or twice each day.<br /><strong>Dosage for Evox 750 mg:</strong><br />- Sinuses: One tablet of Evox 750 mg, once each day.<br />- Pneumonia: One tablet of Evox 750 mg once each day.<br />- Skin and underneath the skin, including muscles: One tablet of Evox 750 mg once each day.<br />&bull; Adults with Kidney problems: Your doctor may need to give you a lower dose.<br />&bull; Children and Teenagers: this medicine must not be given to children or teenagers.<br />&bull; If you miss a dose of Evox, take it as soon as you remember. Do not take more than 1 dose in 1 day.<br />&bull; If you accidentally take more tablets than you should, tell a doctor or get other medical advice straight away.<br />Take the medicine pack with you. This is so the doctor knows what you have taken. The following effects may happen: convulsive fits (seizures), feeling confused, dizzy, less conscious and heart problem leading to uneven heart beats as well as feeling sick (nausea).<br />&bull; Do not skip any doses of Evox or stop taking it, even if you begin to feel better, until you finish your prescribed treatment unless:<br />- you have tendon problems. See &ldquo;What is the most important information I should know about Levofloxacin?&rdquo;.</p><p>- you have a serious allergic reaction. See &ldquo;What are the possible side effects of levofloxacin?&rdquo;.</p><p>- your healthcare provider tells you to stop taking Levofloxacin.<br />Taking all of your Levofloxacin doses will help make sure that all of the bacteria are killed. Taking all of your Levofloxacin doses will help you lower the chance that the bacteria will become resistant to Levofloxacin. If your infection does not get better while you take Levofloxacin, it may mean that the bacteria causing your infection may be resistant to Levofloxacin. If your infection does not get better, call your healthcare provider. If your infection does not get better, Levofloxacin and other similar antibiotic medicines may not work for you in the future.<br />&bull; If you take too much Levofloxacin, call your healthcare provider or get medical help right away.</p><p><strong>WHAT SHOULD I AVOID WHILE TAKING LEVOFLOXACIN?</strong></p><p>&bull; Levofloxacin can make you feel dizzy and lightheaded. Do not drive, operate machinery, or do other activities that require mental alertness or coordination until you know how Levofloxacin affects you.<br />&bull; Avoid sunlamps, tanning beds, and try to limit your time in the sun. Levofloxacin can make your skin sensitive to the sun (photosensitivity) and the light from sunlamps and tanning beds. You could get severe sunburn, blisters or swelling of your skin. If you get any of these symptoms while you take Levofloxacin, call your healthcare provider right away. You should use a sunscreen and wear a hat and clothes that cover your skin if you have to be in sunlight.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Levofloxacin can cause serious side effects, including:<br />&bull; See &ldquo;What is the most important information I should know about Levofloxacin?&rdquo;</p><p><strong>&bull; Serious allergic reactions.</strong><br />Allergic reactions can happen in people taking fluoroquinolones, including Levofloxacin, even after only 1 dose.<br />Stop taking Levofloxacin and get emergency medical help right away if you have any of the following symptoms of a severe allergic reaction:<br />- hives. - trouble breathing or swallowing. - swelling of the lips, tongue, face.<br />- throat tightness, hoarseness. - rapid heartbeat. - faint. - skin rash.<br />Skin rash may happen in people taking Levofloxacin, even after only 1 dose. Stop taking Levofloxacin at the first sign of a skin rash and call your healthcare provider. Skin rash may be a sign of a more serious reaction to Levofloxacin.</p><p><strong>&bull; Liver damage (hepatotoxicity): </strong>Hepatotoxicity can happen in people who take Levofloxacin. Call your healthcare provider right away if you have unexplained symptoms such as:<br />- nausea or vomiting. - stomach pain. - fever. - weakness. - abdominal pain or tenderness.<br />- itching. - unusual tiredness. - loss of appetite. - light colored bowel movements.<br />- dark colored urine. - yellowing of your skin or the whites of your eyes.<br />Stop taking Levofloxacin and tell your healthcare provider right away if you have yellowing of your skin or white part of your eyes, or if you have dark urine. These can be signs of a serious reaction to Levofloxacin (a liver problem).</p><p><strong>&bull; Central Nervous System Effects: </strong>Seizures have been reported in people who take fluoroquinolone antibiotics including Levofloxacin. Tell your healthcare provider if you have a history of seizures. Ask your healthcare provider whether taking Levofloxacin will change your risk of having a seizure.<br />Central Nervous System (CNS) side effects may happen as soon as after taking the first dose of Levofloxacin.<br />Talk to your healthcare provider right away if you get any of these side effects, or other changes in mood or behavior:<br />- seizures. - hear voices, see things, or sense things that are not there (hallucinations).<br />- feel restless. - tremors. - feel anxious or nervous. - confusion. - depression.<br />- trouble sleeping. - nightmares. - feel lightheaded. - feel more suspicious (paranoia).<br />- suicidal thoughts or acts. - a headache that will not go away, with or without blurred vision.</p><p><strong>&bull; Intestine infection (Pseudomembranous colitis)</strong> Pseudomembranous colitis can happen with many antibiotics, including Levofloxacin. Call your healthcare provider right away if you get watery diarrhea, diarrhea that does not go away, or bloody stools. You may have stomach cramps and a fever. Pseudomembranous colitis can happen 2 or more months after you have finished your antibiotic.</p><p><strong>&bull; Changes in sensation and nerve damage (Peripheral Neuropathy)</strong><br />Damage to the nerves in arms, hands, legs, or feet can happen in people taking fluoroquinolones, including Levofloxacin. Stop Levofloxacin and talk with your healthcare provider right away if you get any of the following symptoms of peripheral neuropathy in your arms, hands, legs, or feet and should be switched to another non-fluoroquinolone antibacterial drug, unless the benefit of continued treatment with a fluoroquinolone outweighs the risk:<br />- pain. - burning. - tingling. - numbness.<br />- weakness The nerve damage may be permanent.<br />- change in sensation to light touch, pain or temperature.<br />Peripheral neuropathy can occur at any time during treatment with fluoroquinolones (may occur soon after these drugs are taken) and can last for months to years after the drug is stopped or be permanent.</p><p><strong>&bull; Serious heart rhythm changes (QT prolongation and torsades de pointes)</strong><br />Tell your healthcare provider right away if you have a change in your heart beat (a fast or irregular heartbeat), or if you faint. Levofloxacin may cause a rare heart problem known as prolongation of the QT interval. This condition can cause an abnormal heartbeat and can be very dangerous. The chances of this happening are higher in people:<br />- who are elderly.<br />- with a family history of prolonged QT interval.<br />- with low blood potassium (hypokalemia).<br />- who take certain medicines to control heart rhythm (antiarrhythmics).</p><p><strong>&bull; Joint Problems</strong><br />Increased chance of problems with joints and tissues around joints in children can happen. Tell your child&rsquo;s healthcare provider if your child has any joint problems during or after treatment with Levofloxacin.</p><p><strong>&bull; Changes in blood sugar</strong><br />People who take Levofloxacin and other fluoroquinolone medicines with oral anti-diabetes medicines or with insulin can get low blood sugar (hypoglycemia) and high blood sugar (hyperglycemia). Follow your healthcare provider&rsquo;s instructions for how often to check your blood sugar. If you have diabetes and you get low blood sugar while taking Levoflxoacin, stop taking Levofloxacin and call your healthcare provider right away. Your antibiotic medicine may need to be changed.<br />&bull; Sensitivity to sunlight (photosensitivity) See &ldquo;What should I avoid while taking Levofloxacin?&rdquo; The most common<br />side effects of Levofloxacin include:<br />- nausea. - headache. - diarrhea. - insomnia. - constipation. - dizziness.<br />In children 6 months and older who take Levofloxacin to treat anthrax disease or plague, vomiting is also common.<br />Levofloxacin may cause false-positive urine screening results for opiates when testing is done with some commercially available kits. A positive result should be confirmed using a more specific test.<br />These are not all the possible side effects of Levofloxacin. Tell your healthcare provider about any side effect that bothers you or that does not go away.</p><p><strong>To report any side effect (s):</strong><br />Contact JOSWE Medical:<br />Phone number: +966568093543<br />Email: Saudipv@josweplant com</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>The National Pharmacovigilance Centre (NPC):<br />o Fax: +966-11-205-7662<br />o SFDA Call Center: 19999<br />o Email: npc.drug@sfda.gov.sa<br />o Website: https://ade.sfda.gov.sa</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Store below 30&deg;C.<br />Do not use any Evox pack that is damaged or shows signs of tampering.<br />Keep all medicines out of the reach of children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>---</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Evox 250: each pack contains 7 film coated tablets.
Evox 500: pack contains 7 film coated tablets, and pack contains 14 film coated tablets.
Evox 750: each pack contains 7 film coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>---</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                04/2024 R2
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">إفوكس (ليفوفلوكساسين)، عبارة عن مضاد حيوي من فئة &quot;فلوروكوينولون&quot;، يمكن أن يسبب تأثيرات جانبية خطيرة. بعض من هذه التأثيرات الجانبية قد يؤدي إلى الموت.</p><p dir="RTL">إذا كنت تعاني أي من هذه التأثيرات الجانبية الخطيرة التالية خلال تناولك إفوكس، احصل على المساعدة الطبية في الحال. استشر الطبيب إذا ما كان عليك أن تتابع تناولك إفوكس.</p><p dir="RTL">1. تمزق&nbsp; الأوتار أو تضخمها (التهاب&nbsp; الأوتار).</p><p dir="RTL">&bull; مشاكل الأوتار يمكن أن تحدث للأشخاص من جميع الأعمار الذين يتناولون ليفوفلوكساسين.&nbsp; الأوتار عبارة عن أوتار قوية تربط العضلات مع العظام.</p><p dir="RTL">بعض مشاكل الأوتار تشمل ألم، تضخم، تمزق، بالإضافة&nbsp; إلى إلتهابها ومن ضمنها (وتر أخيل المعروف أيضا بوتر العرقوب) في مؤخرة الكاحل، الكتف، اليد، أو أي أوتار أخرى.</p><p dir="RTL">&bull; تزيد مخاطر حدوث مشاكل في الأوتار خلال فترة تناول ليفوفلوكساسين إذا كنت:</p><p dir="RTL">- أكثر من 60 عاما.</p><p dir="RTL">- تتناول الستيرويد.</p><p dir="RTL">- قمت بعملية زراعة لأحد الأعضاء التالية: الكلية، القلب أو الرئة.</p><p dir="RTL">&bull; مشاكل الأوتار يمكن أن تحدث للأشخاص الذين ليس لديهم أي من عوامل الخطورة السابقة عندما يتناولون ليفوفلوكساسين.</p><p dir="RTL">&bull; الأسباب الأخرى التي تزيد إمكانية الإصابة بمشاكل الأوتار:</p><p dir="RTL">- المجهود الجسدي أو التمارين الرياضية.</p><p dir="RTL">- فشل فى عمل الكلية.</p><p dir="RTL">- مشاكل سابقة مع الأوتار مثل الأشخاص المصابون بالتهاب المفاصل الروماتيزمي.</p><p dir="RTL">اتصل بطبيبك فور ملاحظة أي ألم أو تضخم أو التهاب في الأوتار. توقف عن تناول ليفوفلوكساسين إلا إذا أخبرك طبيبك بأنه تم السيطرة على التهاب الأوتار أو تمزقها. تجنب ممارسة الرياضة أو استخدام المنطقة المتأثرة.</p><p dir="RTL">من الأوتار الأكثر عرضة للإصابة بالألم والتضخم هي (وتر أخيل المعروف بوتر العرقوب) في مؤخرة الكاحل. كما يمكن أن يحدث في أوتار أخرى من الجسم. تكلم مع طبيبك عن خطورة تمزق&nbsp; الأوتار مع استمرارية استعمال ليفوفلوكساسين. يمكن أن تكون بحاجة&nbsp; إلى نوع أخر من المضاد الحيوي غير الفلوروكوينولون لمعالجة الالتهاب الذي أصابك.</p><p dir="RTL">تمزق&nbsp; الأوتار يمكن أن يحدث خلال تناول ليفوفلوكساسين أو بعد الإنتهاء منه.&nbsp; حيث حدث تمزق في الأوتار بعد عدة شهور من تعاطي بعض الأشخاص للفلوروكوينولون.</p><p dir="RTL">- احصل على المساعدة الطبية في الحال إذا ما ظهرت أي من هذه الأعراض التالية:</p><p dir="RTL">- سمعت أو شعرت بقرقعة في مكان&nbsp; الأوتار.</p><p dir="RTL">- رضوض بعد الإصابة في منطقة&nbsp; الأوتار.</p><p dir="RTL">- عدم القدرة على تحريك المنطقة المتاثرة أو تحمل الوزن.</p><p dir="RTL">2. تراجع حالة الوهن العضلي myasthenia gravis (مشكلة تؤدي&nbsp; إلى ضعف العضلات). الفلوروكوينولون ومنها الليفوفلوكساسين يمكن أن تسبب أعراض تراجع الوهن العضلي التي تضم ضعف العضلات وصعوبة في التنفس. اتصل بطبيبك فورا إذا واجهت أي ضعف في العضلات أو صعوبة في التنفس.</p><p dir="RTL">&bull; انظر &quot;ما هي التأثيرات الجانبية المحتملة لليفوفلوكساسين؟&quot;</p><p dir="RTL"><strong>ما هو إفوكس؟</strong></p><p dir="RTL">إفوكس (ليفوفلوكساسين) عبارة عن مضاد حيوي من فئة فلوروكوينولون يستعمل للبالغين من عمر 18 وما فوق لعلاج التهابات معينة سببها جراثيم تسمى البكتيريا. وهذه الالتهابات البكتيرية تشمل:</p><p dir="RTL">&bull; الجيوب.</p><p dir="RTL">&bull; ذات الرئة، للأشخاص المصابون بمشاكل التنفس الدائمة أو الالتهاب الرئوي.</p><p dir="RTL">&bull; المسالك البولية، وتشمل الكلية والمثانة.</p><p dir="RTL">&bull; الغدة البروستاتية، عندما يكون هناك التهاب مزمن.</p><p dir="RTL">&bull; الجلد وما تحت الجلد، بما في ذلك العضلات. وهو ما يسمى أحيانا &quot;بالأنسجة الرخوة&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول ليفوفلوكسانين إذا كنت قد أصبت بأي حساسية خطرة اتجاه أي مضاد حيوي أخر من فئة فلوروكينولون، أو إذا كنت تعاني حساسية لليفوفلوكساسين.</p><p dir="RTL">ماذا يجب أن تخبر طبيبك قبل تناول ليفوفلوكساسين؟</p><p dir="RTL">قبل ان تتناول ليفوفلوكساسين، أعلم طبيبك في الحالات التالية:</p><p dir="RTL">&bull; لديك مشاكل بالأوتار.</p><p dir="RTL">&bull; لديك مشكلة تسبب ضعف العضلات (myasthenia gravis).</p><p dir="RTL">&bull; لديك مشاكل بجهاز الأعصاب المركزي مثل نوبة الصرع.</p><p dir="RTL">&bull; لديك مشاكل بالأعصاب.</p><p dir="RTL">&bull; لديك أو لدى أي فرد بالأسرة نبض دقات القلب غير منتظم، وخاصة في الحالات التي تعرف ب متلازمة إطالة QT.</p><p dir="RTL">&bull; لديك انخفاض بتركيز البوتاسيوم بالدم.</p><p dir="RTL">&bull; لديك مشاكل بالعظام.</p><p dir="RTL">&bull; لديك مشاكل بالمفاصل والذي يضم التهاب الروماتيزم.</p><p dir="RTL">&bull; لديك مشاكل بالكلى، عندها تحتاج لجرعة أقل من ليفوفلوكساسين إذا كانت كليتيك لا تعملان جيدا.</p><p dir="RTL">&bull; لديك مشاكل بالكبد.</p><p dir="RTL">&bull; لديك سكري أو مشاكل بانخفاض السكر في الدم.</p><p dir="RTL">&bull; إذا كنت حامل أو تخططين للإنجاب. لم يذكر بأن ليفوفلوكساسين قد يؤذي الجنين.</p><p dir="RTL">&bull; إذا كنت ترضعين أو تخططين للإرضاع. لم يذكر بأن ليفوفلوكساسين قد يفرز في حليب الصدر. يجب عليك وعلى طبيبك اختيار إما تناول الدواء أو الإرضاع. يجب عليك ألا تقومي بالإثنين معا.</p><p dir="RTL">&bull; اذا تم تشخيصك من قبل بتضخم أو انتفاخ في الاوعية الدموية (تمدد الاوعية الدموية الابهري او تمدد الاوعية الدموية الطرفي).</p><p dir="RTL">&bull; اذا كنت قد تعرضت مسبقا لتسلخ الابهر (تمزق في جدار الشريان الابهر).</p><p dir="RTL">&bull; اذا كان لديك تاريخ عائلي في تمدد الاوعية الدموية الابهرية او تسلخ الابهر او عوامل خطر اخرى (مثل اضطرابات النسيج الضام مثل متلازمة مارفان، او متلازمة اهلرز-دانلوس او اضطرابات الاوعية الدموية مثل التهاب الشريان التاكاياسو، التهاب الشرايين الخلوي او مرض بهجت او ارتفاع ضغط الدم او تصلب الشرايين المعروف).</p><p dir="RTL">اذا شعرت بألم شديد مفاجئ في بطنك او صدرك او ظهرم، فم بالذهاب الى الطوارئ على الفور.</p><p dir="RTL">يجب أن تخبر الطبيب بجميع الأدوية التي تأخذها، بما في ذلك الأدوية التي تصرف بوصفة طبية أو بدون وصفة، والفيتامينات والمكملات العشبية.</p><p dir="RTL">ليفوفلوكساسين والأدوية الأخرى يمكن أن تؤثر فيما بينها مسببة تأثيرات جانبية.</p><p dir="RTL">أخبر طبيبك خاصة إذا كنت تأخذ:</p><p dir="RTL">&bull; الستيرويدات.</p><p dir="RTL">&bull; دواء منع الهذيان.</p><p dir="RTL">&bull; مضاد الاكتئاب ثلاثي الحلقات.</p><p dir="RTL">&bull; مدر البول.</p><p dir="RTL">&bull; والأدوية التالية يمكن أن تؤثر على كيفية عمل ليفوفلوكساسين. تناول أقراص ليفوفلوكساسين ساعتان قبل أو ساعتان بعد تناول هذه الأدوية أو المكملات:</p><p dir="RTL">- مضاد الحموضة، الفيتامينات، أو أي أدوية أو مكملات أخرى تحتوي على المغنيسيوم، الألمنيوم، الحديد أو الزنك.</p><p dir="RTL">- سكرالفات.</p><p dir="RTL">- ديدانوسين.</p><p dir="RTL">- دواء مضاد لتجلط الدم (وارفارين، كومادين، جانتوفين).</p><p dir="RTL">- أدوية السكري التي تؤخذ عن طريق الفم أو الأنسولين.</p><p dir="RTL">- مضاد الالتهاب الغير ستيرودي (NSAID) العديد من الأدوية الشائعة لتسكين الألم عبارة عن (NSAID) . تناولك ل (NSAID) خلال فترة تناولك ليفوفلوكساسين أو فلوروكوينولون بإمكانه أن يزيد من خطورة تأثر اصابة جهازك العصبي وإصابتك بالصرع.</p><p dir="RTL">- ثيوفيلين.</p><p dir="RTL">- الأدوية التي تنظم ضربات القلب.</p><p dir="RTL">استشر طبيبك&nbsp; إذا لم تكن متاكدا من أن أحد أدويتك هو من الأدوية المذكورة أعلاه.</p><p dir="RTL">تعرف على الدواء الذي تأخذه، قم بعمل لائحة بأدويتك واعرضها على طبيبك&nbsp; أو الصيدلي عند حصولك على دواء جديد.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&bull; تناول إفوكس تماما كما أخبرك طبيبك&nbsp; بأن تأخذه.</p><p dir="RTL">&bull; تناول هذا الدواء عبر الفم.</p><p dir="RTL">&bull; تناول الأقراص كاملة مع الماء.</p><p>&bull; تناول إفوكس بنفس الوقت كل يوم</p><p dir="RTL">&bull; يمكن تناول أقراص إفوكس مع أو بدون الطعام.</p><p dir="RTL">كم يجب أن تتناول من إفوكس؟</p><p dir="RTL">&bull; سيقرر طبيبك عدد الأقراص التي يجب عليك تناولها.</p><p dir="RTL">&bull; تتوقف الجرعة على نوع الالتهاب الذي أصابك ومكانه في جسمك.</p><p dir="RTL">&bull; تتوقف مدة علاجك على مدى خطورة الالتهاب الذي أصابك.</p><p dir="RTL">&bull; إذا شعرت بأن تأثير الدواء ضعيف أو قوي، لا تغير الجرعة من تلقاء نفسك، بل استشر طبيبك.</p><p dir="RTL">&bull; الخط المنقوش على إفوكس 250 و500 هو للتمييز فقط، ولا يمكن كسر القرص إلى جزئين.</p><p dir="RTL">&bull; البالغون وكبار السن.</p><p dir="RTL"><strong>جرعة إفوكس 250 ملغم و 500 ملغم:</strong></p><p dir="RTL">- الجيوب : قرصين من إفوكس 250 ملغم مرة واحدة يوميا أو قرص واحد من إفوكس 500 ملغم مرة واحدة يوميا.</p><p dir="RTL">- التهاب الرئة، للمرضى الذين يعانون من مشاكل تنفسية طويلة الأمد: قرص أو قرصين من إفوكس 250 ملغم، مرة واحدة يوميا أو قرص واحد من إفوكس 500 ملغم مرة واحدة يوميا.</p><p dir="RTL">- ذات الرئة: قرصين من إفوكس 250 ملغم مرة واحدة أو مرتين يوميا أو قرص واحد 500 ملغم مرة واحدة أو مرتين يوميا.</p><p dir="RTL">- التهاب المسالك البولية، ويشمل الكليتان أو المثانة: قرص واحد من إفوكس 250 ملغم يوميا.</p><p dir="RTL">- التهاب الغدة البروستاتية: قرصين من إفوكس 250 ملغم يوميا. أو قرص واحد&nbsp; 500 ملغم مرة واحدة يوميا.</p><p dir="RTL">- التهاب الجلد وما تحت الجلد، ويشمل التهاب العضلات: قرص واحد أو اثنين من إفوكس 250 ملغم مرة واحدة&nbsp; أو مرتين يوميا أو قرص واحد&nbsp; 500 ملغم مرة واحدة&nbsp; أو مرتين يوميا.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p dir="RTL">&nbsp;<strong>جرعة إفوكس 750 ملغم:</strong></p><p dir="RTL">- التهاب&nbsp; الجيوب: قرص واحد 750 ملغم مرة واحدة يوميا.</p><p dir="RTL">- ذات الرئة: قرص واحد&nbsp; 750 ملغم مرة واحدة يوميا.</p><p dir="RTL">- التهاب الجلد وما تحت الجلد، ويشمل التهاب العضلات: قرص واحد 750 ملغم مرة واحدة يوميا.</p><p dir="RTL">&bull; للبالغين الذين يعانون من مشاكل في الكلى: قد يضطر الطبيب إلى إعطائك جرعة أقل.</p><p dir="RTL">&bull; للأطفال والمراهقين: يمنع اعطاء هذا الدواء&nbsp; للأطفال أو المراهقين.</p><p dir="RTL">&bull; في حالة أنك نسيت تناول جرعة إفوكس قم بتناولها حالما تذكرت. لا تتناول أكثر من جرعة واحدة يوميا.</p><p dir="RTL">&bull; في حالة أنك تناولت من غير قصد أكثر من جرعة واحدة، يجب عليك أن تخبر طبيبك أو تحصل فورا على أي استشارة طبية.&nbsp; وخذ علبة الدواء معك، و ذلك لكي يعرف الطبيب كم تناولت من الدواء.</p><p dir="RTL">قد تحدث إحدى الأعراض التالية: نوبات تشنجية (الصرع)، أن تشعر بالإرتباك، دوخة، قلة الوعي ومشاكل في القلب قد تؤدي إلى حدوث ضربات قلب غير منتظمة كما أنه من الممكن أن تشعر بالغثيان.</p><p dir="RTL">&bull; لا تتجنب أي جرعة من جرعات إفوكس أو تتوقف عن تناولها حتى لو بدأت تشعر بتحسن إلا أن تنتهي من العلاج الموصوف إلا في الحالات التالية:</p><p dir="RTL">- لديك مشاكل في&nbsp; الأوتار. انظر &quot;ما هي أهم المعلومات التي يجب معرفتها عن إفوكس (ليفوفلوكساسين)؟&quot;.</p><p dir="RTL">- لديك رد فعل حساسية خطير. انظر &quot;ما هي الأعراض الجانبية المحتملة لليفوفلوكساسين؟&quot;.</p><p dir="RTL">- عندما يطلب منك طبيبك أن تتوقف عن تناول ليفوفلوكساسين.</p><p dir="RTL">تناولك للجرعة الكاملة من ليفوفلوكساسين تساعدك على التأكد من أنه قد تم القضاء على البكتيريا. كما ستساعد على تقليل فرصة مقاومة البكتيريا لليفوفلوكساسين. إذا لم تجد أي تحسن خلال فترة تناولك لليفوفلوكساسين فذلك يعني بأن البكتيريا المسببة للالتهاب مقاومة لليفوفلوكساسين. إذا لم يكن هنالك أي تحسن بالالتهاب يجب عليك أن تتصل بطبيبك. إذا لم يكن هنالك أي تحسن فذلك يعني بأن ليفوفلوكساسين وأي مضادات حيوية مشابهة له من الممكن أنها لا تعمل بالشكل الفعال بالنسبة لك في المستقبل.</p><p dir="RTL">&bull; إذا كنت تناولت الكثير من ليفوفلوكساسين، اتصل بطبيبك أو احصل على المساعدة الطبية في الحال.</p><p dir="RTL">ما هي الأمور التي يجب تجنبها خلال تناول ليفوفلوكساسين؟</p><p dir="RTL">&bull; من الممكن أن يشعرك ليفوفلوكساسين بالدوخة والدوار. لا تقد سيارة أو تشغيل آلات أو أي عمل يتطلب مستوى عالٍ من التركيز حتى تتعرف على تأثير الليفوفلوكساسين عليك.</p><p dir="RTL">&bull; تجنب التعرض إلى أشعة الشمس، وقلل من مدة تعرضك لأشعة الشمس. ليفوفلوكساسين يجعل بشرتك أكثر حساسية اتجاه الشمس .</p><p dir="RTL">وقد يحدث لك حروق أو بثور أو تورم من أشعة الشمس. إذا حصل لك أي من تلك الأعراض خلال فترة تناولك لليفوفلوكساسين استشر طبيبك&nbsp; على الفور. لذلك احرص على&nbsp; استخدام&nbsp; مرهم واقي من أشعة&nbsp; الشمس،ارتد قبعة وثياب تغطي بشرتك إذا كنت مضطرا إلى التعرض إلى أشعة الشمس.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ليفوفلوكساسين يمكن أن يسبب أعراض جانبية خطيرة، مثل:</p><p dir="RTL">&bull; انظر &quot;ما هي أهم المعلومات التي يجب معرفتها عن إفوكس (ليفوفلوكساسين)؟&quot;</p><p dir="RTL"><strong>&bull; ردود فعل حساسية خطيرة.</strong></p><p dir="RTL">رد الفعل التحسسي يمكن أن يحدث للأشخاص الذين يتناولون فلوروكوينولونز، ومنها ليفوفلوكساسين، حتى لو بعد جرعة واحدة. توقف عن تناول ليفوفلوكساسين واحصل على مساعدة طبية فورية في الحال إذا ظهرت لك أي من هذه الأعراض الخطيرة لردود الفعل التحسسية:</p><p dir="RTL">- شرى.&nbsp;&nbsp;&nbsp;&nbsp; - صعوبة في التنفس أو البلع.&nbsp;&nbsp;&nbsp;&nbsp; - انتفاخ الشفتين، اللسان والوجه.</p><p dir="RTL">- ضيق في الحلق وبحة الصوت.&nbsp;&nbsp;&nbsp;&nbsp; - تسارع ضربات القلب.&nbsp;&nbsp;&nbsp;&nbsp; - إغماء.&nbsp;&nbsp;&nbsp;&nbsp; - طفح جلدي.</p><p dir="RTL">الطفح الجلدي يمكن أن يصيب الأشخاص الذين يتناولون ليفوفلوكساسين، حتى لو بعد جرعة واحدة فقط. لذلك يجب عليك أن تتوقف عن تناول الليفوفلوكساسين عند أول ملاحظة لعلامات ظهور الطفح الجلدي وقم باستشارة طبيبك المعالج.</p><p dir="RTL">قد يكون الطفح الجلدي مؤشر على المزيد من الأعراض الخطيرة الأخرى لليفوفلوكساسين.</p><p dir="RTL"><strong>&bull; تضرر الكبد (تسمم الكبد)</strong>: تسمم الكبد يمكن أن يصيب الأشخاص الذين يتناولون ليفوفلوكساسين. استشر طبيبك على الفور إذا كنت تعاني من هذه الأعراض الغير مفسرة:</p><p dir="RTL">- غثيان أو قئ.&nbsp;&nbsp;&nbsp;&nbsp; - ألم في البطن.&nbsp;&nbsp;&nbsp;&nbsp; - حمى.&nbsp;&nbsp;&nbsp;&nbsp; - ضعف عام.&nbsp;&nbsp;&nbsp;&nbsp; - آلام في البطن.</p><p dir="RTL">- حكة.&nbsp;&nbsp;&nbsp;&nbsp; - تعب غير طبيعي.&nbsp;&nbsp;&nbsp;&nbsp; - فقدان الشهية&nbsp;&nbsp;&nbsp;&nbsp; - حركة خفيفة للأمعاء.</p><p dir="RTL">- لون داكن للبول.&nbsp;&nbsp;&nbsp;&nbsp; - اصفرار الجلد أو اصفرار بياض العين.</p><p dir="RTL">توقف عن تناول ليفوفلوكساسين واستشر طبيبك على الفور إذا ظهر عليك اصفرار الجلد أو&nbsp; اصفرار بياض العين، أو إذا لاحظت اللون الداكن للبول. هذه قد تكون من الأعراض الخطيرة لليفوفلوكساسين (مشاكل في الكبد).</p><p dir="RTL"><strong>&bull; التأثيرات على الجهاز العصبي المركزي:</strong> سجل حدوث نوبات صرع لدى الأشخاص الذين يتناولون المضاد الحيوي فلوروكوينولون ومنها ليفوفلوكساسين. أخبر طبيبك&nbsp; إذا ما كان لك سجل مرضي مع نوبات الصرع. اسأل طبيبك إذا ما كان ليفوفلوكساسين يؤثر على إمكانية الإصابة بنوبات الصرع.</p><p dir="RTL">التأثيرات الجانبية التي تصيب الجهاز العصبي المركزي قد تحدث فور تناولك للجرعة الأولى من الليفوفلوكساسين. استشر طبيبك على الفور إذا ظهرت لك أي من هذه التأثيرات الجانبية أو أي إختلافات على المزاج&nbsp; أو السلوك:</p><p dir="RTL">- نوبات الصرع.&nbsp;&nbsp;&nbsp;&nbsp; - أن تسمع أصوات وترى أشياء وتشعر بأشياء هي في الواقع غير موجودة (الهلوسات).</p><p dir="RTL">- الشعور بعدم الراحة.&nbsp;&nbsp;&nbsp;&nbsp; - رجفة.&nbsp;&nbsp;&nbsp;&nbsp; - الشعور بالقلق أو التوتر.&nbsp;&nbsp;&nbsp;&nbsp; - اضطراب.&nbsp;&nbsp;&nbsp;&nbsp; - اكتئاب.</p><p dir="RTL">- صعوبة في النوم.&nbsp;&nbsp;&nbsp;&nbsp; - كوابيس.&nbsp;&nbsp;&nbsp;&nbsp; - الشعور بالدوار.&nbsp;&nbsp;&nbsp;&nbsp; - الشعور بالإرتياب.</p><p dir="RTL">- أفكار بالانتحار أو أفعال.&nbsp;&nbsp;&nbsp;&nbsp; - صداع دائم، مع أو بدون رؤية غير واضحة.</p><p dir="RTL"><strong>&bull; التهاب الأمعاء (التهاب شبه غشاء القولون):</strong> التهاب شبه غشاء القولون يمكن أن يحدث مع الكثير من المضادات الحيوية من ضمنها الليفوفلوكساسين. استشر طبيبك في الحال إذا أصبت بالإسهال المائي، أو إسهال دائم أو لاحظت دم مع البراز. يمكن أن يصيبك تشنجات معوية بالإضافة إلى الحمى. التهاب شبه غشاء القولون يمكن أن يصيبك بعد شهرين أو أكثر من تناولك للمضاد الحيوي.</p><p dir="RTL"><strong>&bull; تغير في الإحساس و تلف الاعصاب (الاعتلال العصبي الطرفي).</strong></p><p dir="RTL">- تلف أعصاب الذراع،&nbsp; اليد، الرجل أو القدم قد يصيب الأشخاص الذين يتناولون فلوروكينولون ومنها الليفوفلوكساسين.&nbsp; توقف عن تناول ليفوفلوكساسين واستشر طبيبك على الفور إذا ما ظهرت عليك أي من الأعراض التالية للاعتلال العصبي الطرفي في الذراع، اليد، الرجل أو القدم كما يجب أن تبدل المضاد الحيوي الحالي بآخر لا يحتوي على الفلوروكوينولون، إلا إذا كانت الفائدة من العلاج المستمر بالفلوروكوينولون أهم من الخطورة:</p><p dir="RTL">- ألم.&nbsp;&nbsp;&nbsp;&nbsp; - حروق.&nbsp;&nbsp;&nbsp;&nbsp; - وخز.&nbsp;&nbsp;&nbsp;&nbsp; - خدر.</p><p dir="RTL">- ضعف عام.&nbsp; قد يكون تلف العصب دائم.</p><p dir="RTL">- تغير في إحساس اللمس الخفيف، وجع أو حرارة.</p><p dir="RTL">- الاعتلال العصبي الطرفي يمكن أن يحدث في أي وقت خلال فترة العلاج بفلوروكوينولون (ويمكن أن يحدث مباشرة بعد تناول هذه الأدوية). ويمكن أن يستمر لشهر أو لسنوات بعد ايقاف العلاج ويمكن ان يكون دائم.</p><p dir="RTL"><strong>&bull; تغيرات خطيرة على نبض القلب (إطالة QT and torsades de pointes)</strong></p><p dir="RTL">استشر طبيبك&nbsp; على الفور إذا لاحظت أي تغيرات على ضربات القلب (سواء كانت متسارعة أو غير منتظمة)، أو شحوب. ليفوفلوكساسين يمكن أن يسبب مشاكل في القلب غير عادية معروفة بإطالة مدة QT.</p><p dir="RTL">هذه الحالة بإمكانها أن تسبب ضربات قلب غير طبيعية وقد تكون خطيرة. إن احتمالية حدوث مثل هذه الأمور تكون عالية لدى الأشخاص التاليين:</p><p dir="RTL">- كبار السن</p><p dir="RTL">- لديهم تاريخ عائلي لمرض اطالة مدة QT.</p><p dir="RTL">- الذين يعانون من نقص البوتاسيوم بالدم.</p><p dir="RTL">- الذين يتناولون أدوية معينة للتحكم بضربات القلب.</p><p dir="RTL"><strong>&bull;مشاكل المفاصل</strong></p><p dir="RTL">زيادة احتمالية الإصابة بمشاكل المفاصل والأنسجة حول المفاصل لدى الأطفال قد تحدث. استشر الطبيب إذا كان الطفل يعاني من مشاكل بالمفاصل خلال أو بعد العلاج بالليفوفلوكساسين.</p><p dir="RTL"><strong>&bull; تغيرات على مستوى السكر في الدم</strong></p><p dir="RTL">الأشخاص الذين يتناولون ليفوفلوكساسين أو أي أدوية تتكون من فلوروكوينولون بالإضافة&nbsp; إلى أدوية السكري التي تؤخذ عن طريق الفم&nbsp; أو إبر الأنسولين يمكن لهم التعرض لانخفاض السكر في الدم وارتفاع السكر في الدم . اتبع تعليمات الطبيب لمعرفة المدة اللازمة للقيام بالفحص الخاص للتأكد من مستوى السكر في الدم. إذا كنت مصاب بالسكري وحصلت على مستوى منخفض للسكر بالدم&nbsp; خلال فترة تناولك لليفوفلوكسانين عليك استشارة طبيبك المعالج في الحال. من الممكن أن تكون بحاجة لتغير المضاد الحيوي.</p><p dir="RTL"><strong>&bull; الحساسية من أشعة الشمس. انظر &quot; ما هي الأمور التي يجب تجنبها خلال تناول ليفوفلوكساسين؟&quot;</strong></p><p dir="RTL">&nbsp;من الأعراض الجانبية الشائعة لليفوفلوكساسين:</p><p dir="RTL">- الغثيان.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - الصداع.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; - الإسهال.&nbsp;&nbsp;&nbsp;&nbsp; - الأرق.&nbsp;&nbsp;&nbsp;&nbsp; - الإمساك.&nbsp;&nbsp;&nbsp;&nbsp; - الدوخة.</p><p dir="RTL">للأطفال بعمر 6 شهور والأكبر الذين يتناولون ليفوفلوكساسين لمعالجة الجمرة الخبيثة أو الطاعون، التقيؤ قد يكون شائعا في مثل هذه الحالات.</p><p dir="RTL">ليفوفلوكساسين قد يسبب نتيجة فحص إيجابية خاطئة للمخدرات عند القيام بالفحص باستعمال أدوات فحص تجارية. للحصول على نتيجة إيجابية مؤكدة يجب استعمال فحص أكثر دقة.</p><p dir="RTL">وهذه ليست كل التأثيرات الجانبية المحتملة لليفوفلوكساسين.&nbsp; أخبر طبيبك&nbsp; عن أية تأثيرات جانبية تزعجك وملازمة لك.</p><p dir="RTL"><strong>للإبلاغ عن أي آثار جانبية:</strong></p><p dir="RTL">التواصل مع الشركة الاردنية السويدية للمنتجات الطبية و التعقيم</p><p dir="RTL">رقم الهاتف: +966568093543</p><p dir="RTL">البريد الالكتروني: saudipv@josweplant.com</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p dir="RTL">المركز الوطني للتيقظ و السلامة الدوائية</p><p dir="RTL">&nbsp;فاكس: +966-11-205-7662</p><p dir="RTL">مركز الاتصال الموحد: 19999</p><p dir="RTL">الايميل: npc.drug@sfda.gov.sa</p><p dir="RTL">&nbsp;الموقع الإلكتروني:&nbsp;https://ade.sfda.gov.sa</p></td></tr></tbody></table><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بدرجة حرارة أقل من 30 درجة مئوية.</p><p dir="RTL">لا تستخدم إفوكس عند ملاحظة أي علامة تلف عليه.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p><p>تحفظ جميع الأدوية بعيدا عن متناول الأطفال.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>---</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إفوكس 250: كل عبوة تحتوي على 7 أقراص مغلفة غشائيا.</p><p dir="RTL">إفوكس 500: كل عبوة تحتوي على 7 اقراص مغلفة غشائيا. و عبوة تحتوي على 14 قرص مغلف غشائيا.</p><p dir="RTL">إفوكس 750: كل عبوة تحتوي على 7 اقراص مغلفة غشائيا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>---</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            04/2024   
R2
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Evox 250 mg film-coated tablets
Evox 500 mg film-coated tablets
Evox 750 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                - Each film-coated tablet of Evox 250 mg contains 250 mg of levofloxacin as levofloxacin hemihydrate.
- Each film-coated tablet of Evox 500 mg contains 500 mg of levofloxacin as levofloxacin hemihydrate.
- Each film-coated tablet of Evox 750 mg contains 750 mg of levofloxacin as levofloxacin hemihydrate.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film Coated Tablet. 

- Evox 250: Yellowish film coated caplet, bisected from one side and embossed by L250 from other side.
- Evox 500: Light yellow to yellow film coated caplet, bisected from one side and embossed by L500 from other side.
- Evox 750: Light yellow to yellow film coated caplet, plain from one side and embossed by L750 from other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Evox is indicated in adults for the treatment of the following infections (see sections 4.4 and 5.1):</p><p>&bull; Acute pyelonephritis and complicated urinary tract infections (see section 4.4)</p><p>&bull; Chronic bacterial prostatitis</p><p>&bull; Inhalation Anthrax: postexposure prophylaxis and curative treatment (see section 4.4)</p><p>In following indication Evox tablets should be used only when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the treatment of these infections.</p><p>&bull; Acute bacterial sinusitis</p><p>&bull; Acute exacerbations of chronic bronchitis obstructive pulmonary disease including bronchitis</p><p>&bull; Community-acquired pneumonia</p><p>&bull; Complicated skin and soft tissue infections</p><p>&bull; Uncomplicated cystitis (see section 4.4)</p><p>Evox may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin.</p><p>Consideration should be given to official guidance on the appropriate use of antibacterial agents</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Evox tablets are administered once or twice daily. The dosage depends on the type and severity of the infection and the susceptibility of the presumed causative pathogen.</p><p>Evox tablets may also be used to complete a course of therapy in patients who have shown improvement during initial treatment with intravenous levofloxacin; given the bioequivalence of the parenteral and oral forms, the same dosage can be used.</p><p><strong>Posology</strong></p><p>The following dose recommendations can be given for Evox:</p><p>Dosage in patients with normal renal function (creatinine clearance &gt; 50 ml/min)</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong><em>Indication </em></strong></p></td><td style="vertical-align:top"><p><strong>Daily dose regimen </strong></p><p><em>(according to severity)</em></p></td><td style="vertical-align:top"><p><strong>Duration of treatment</strong></p><p><em>(according to severity)</em></p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Acute bacterial sinusitis</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>10 - 14 days</p></td></tr><tr><td style="vertical-align:top"><p>750 mg once daily</p></td><td style="vertical-align:top"><p>5 days</p></td></tr><tr><td style="vertical-align:top"><p>Acute bacterial exacerbations of chronic bronchitis</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>7 - 10 days</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Community-acquired pneumonia</p></td><td style="vertical-align:top"><p>500 mg once or twice daily</p></td><td style="vertical-align:top"><p>7 - 14 days</p></td></tr><tr><td style="vertical-align:top"><p>750 mg once daily</p></td><td style="vertical-align:top"><p>5 days</p></td></tr><tr><td style="vertical-align:top"><p>Pyelonephritis</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>7 - 10 days</p></td></tr><tr><td style="vertical-align:top"><p>Complicated urinary tract infections</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>7 &ndash; 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Uncomplicated cystitis</p></td><td style="vertical-align:top"><p>250mg once daily</p></td><td style="vertical-align:top"><p>3 days</p></td></tr><tr><td style="vertical-align:top"><p>Chronic bacterial prostatitis</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>28 days</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Complicated skin and soft tissue infections</p></td><td style="vertical-align:top"><p>500 mg once or twice daily</p></td><td style="vertical-align:top"><p>7 - 14 days</p></td></tr><tr><td style="vertical-align:top"><p>750 mg once daily</p></td><td style="vertical-align:top"><p>7 - 14 days</p></td></tr><tr><td style="vertical-align:top"><p>Inhalation Anthrax</p></td><td style="vertical-align:top"><p>500 mg once daily</p></td><td style="vertical-align:top"><p>8 weeks</p></td></tr></tbody></table><p><u>Special populations</u></p><p>Impaired renal function (creatinine clearance &le; 50 ml/min)</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td colspan="3" style="vertical-align:top"><p>Dose regimen</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>250 mg/24 h</p></td><td style="vertical-align:top"><p>500 mg/24 h</p></td><td style="vertical-align:top"><p>500 mg/12 h</p></td></tr><tr><td style="vertical-align:top"><p>Creatinine clearance</p></td><td style="vertical-align:top"><p>first dose: 250 mg</p></td><td style="vertical-align:top"><p>first dose: 500 mg</p></td><td style="vertical-align:top"><p>first dose: 500 mg</p></td></tr><tr><td style="vertical-align:top"><p>50-20 ml/min</p></td><td style="vertical-align:top"><p>then: 125 mg/24 h</p></td><td style="vertical-align:top"><p>then: 250 mg/24 h</p></td><td style="vertical-align:top"><p>then: 250 mg/12 h</p></td></tr><tr><td style="vertical-align:top"><p>19-10 ml/min</p></td><td style="vertical-align:top"><p>then: 125 mg/48 h</p></td><td style="vertical-align:top"><p>then: 125 mg/24 h</p></td><td style="vertical-align:top"><p>then: 125 mg/12 h</p></td></tr><tr><td style="vertical-align:top"><p>&lt; 10 ml/min (including haemodialysis and CAPD) 1</p></td><td style="vertical-align:top"><p>then: 125 mg/48 h</p></td><td style="vertical-align:top"><p>then: 125 mg/24 h</p></td><td style="vertical-align:top"><p>then: 125 mg/24 h</p></td></tr></tbody></table><p><sup>1</sup> No additional doses are required after haemodialysis or continuous ambulatory peritoneal dialysis (CAPD).</p><p>Impaired liver function</p><p>No adjustment of dose is required since levofloxacin is not metabolised to any relevant extent by the liver and is mainly excreted by the kidneys.</p><p>Elderly Population</p><p>No adjustment of dose is required in the elderly, other than that imposed by consideration of renal function (See section 4.4 &ldquo;Tendinitis and tendon rupture&rdquo; and &ldquo;QT interval prolongation&rdquo;).</p><p>Paediatric population</p><p>Evox is contraindicated in children and growing adolescents (see section 4.3).</p><p><strong>Method of administration </strong></p><p>Evox tablets should be swallowed without crushing and with sufficient amount of liquid. They may be divided at the score line to adapt the dose. The tablets may be taken during meals or between meals. Evox tablets should be taken at least two hours before or after iron salts, zinc salts, magnesium- or aluminium-containing antacids, or didanosine (only didanosine formulations with aluminium or magnesium containing buffering agents), and sucralfate administration, since reduction of absorption can occur (see section 4.5).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Levofloxacin must not be used: 
• in patients hypersensitive to levofloxacin or other quinolones or any of the excipients listed in section 6.1, 
• in patients with epilepsy, 
• in patients with history of tendon disorders related to fluoroquinolone administration, 
• in children or growing adolescents, 
• during pregnancy, 
• in breast-feeding women

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of levofloxacin should be avoided in patients who have experienced serious adverse reactions in the past when using quinolone or fluoroquinolone containing products (see section 4.8). Treatment of these patients with levofloxacin should only be initiated in the absence of alternative treatment options and after careful benefit/risk assessment (see also section 4.3).</p><p>Risks of resistance</p><p>Methicillin-resistant S. aureus are very likely to possess co-resistance to fluoroquinolones, including levofloxacin. Therefore levofloxacin is not recommended for the treatment of known or suspected MRSA infections unless laboratory results have confirmed susceptibility of the organism to levofloxacin (and commonly recommended antibacterial agents for the treatment of MRSA-infections are considered inappropriate).</p><p>Levofloxacin may be used in the treatment of Acute Bacterial Sinusitis and Acute Exacerbation of Chronic Bronchitis when these infections have been adequately diagnosed.</p><p>Resistance to fluoroquinolones of E. coli &ndash; the most common pathogen involved in urinary tract infections &ndash; varies across the European Union. Prescribers are advised to take into account the local prevalence of resistance in E. coli to fluoroquinolones.</p><p>Inhalation Anthrax: Use in human is based on in vitro Bacillus anthracis susceptibility data and on animal experimental data together with limited human data. Treating physicians should refer to national and/or international consensus documents regarding the treatment of anthrax.</p><p>Prolonged, disabling and potentially irreversible serious adverse drug reactions</p><p>Very rare cases of prolonged (continuing months or years), disabling and potentially irreversible serious adverse drug reactions affecting different, sometimes multiple, body systems (musculoskeletal, nervous, psychiatric and senses) have been reported in patients receiving quinolones and fluoroquinolones irrespective of their age and pre-existing risk factors. Levofloxacin should be discontinued immediately at the first signs or symptoms of any serious adverse reaction and patients should be advised to contact their prescriber for advice.</p><p>Tendinitis and tendon rupture</p><p>Tendinitis and tendon rupture (especially but not limited to Achilles tendon), sometimes bilateral, may occur as early as within 48 hours of starting treatment with quinolones and fluoroquinolones and have been reported to occur even up to several months after discontinuation of treatment. The risk of tendinitis and tendon rupture is increased in older patients, patients with renal impairment, patients with solid organ transplants, in patients receiving daily doses of 1000 mg and those treated concurrently with corticosteroids. Therefore, concomitant use of corticosteroids should be avoided. At the first sign of tendinitis (e.g. painful swelling, inflammation) the treatment with levofloxacin should be discontinued and alternative treatment should be considered. The affected limb(s) should be appropriately treated (e.g. immobilisation). Corticosteroids should not be used if signs of tendinopathy occur</p><p>Clostridium difficile-associated disease</p><p>Diarrhoea, particularly if severe, persistent and/or bloody, during or after treatment with levofloxacin (including several weeks after treatment), may be symptomatic of Clostridium difficile-associated disease (CDAD). CDAD may range in severity from mild to life threatening, the most severe form of which is pseudomembranous colitis (see section 4.8). It is therefore important to consider this diagnosis in patients who develop serious diarrhoea during or after treatment with levofloxacin. If CDAD is suspected or confirmed, levofloxacin should be stopped immediately and appropriate treatment initiated without delay. Anti-peristaltic medicinal products are contraindicated in this clinical situation.</p><p>Patients predisposed to seizures</p><p>Quinolones may lower the seizure threshold and may trigger seizures. Levofloxacin is contraindicated in patients with a history of epilepsy (see section 4.3) and, as with other quinolones, should be used with extreme caution in patients predisposed to seizures or concomitant treatment with active substances that lower the cerebral seizure threshold, such as theophylline (see section 4.5). In case of convulsive seizures (see section 4.8), treatment with levofloxacin should be discontinued.</p><p>Patients with G-6- phosphate dehydrogenase deficiency</p><p>Patients with latent or actual defects in glucose-6-phosphate dehydrogenase activity may be prone to haemolytic reactions when treated with quinolone antibacterial agents. Therefore, if levofloxacin has to be used in these patients, potential occurrence of haemolysis should be monitored.</p><p>Patients with renal impairment</p><p>Since levofloxacin is excreted mainly by the kidneys, the dose of Evox should be adjusted in patients with renal impairment (see section 4.2).</p><p>Hypersensitivity reactions</p><p>Levofloxacin can cause serious, potentially fatal hypersensitivity reactions (e.g. angioedema up to anaphylactic shock), occasionally following the initial dose (see section 4.8). Patients should discontinue treatment immediately and contact their physician or an emergency physician, who will initiate appropriate emergency measures.</p><p>Severe cutaneous adverse reactions</p><p>Severe cutaneous adverse reactions (SCARs) including toxic epidermal necrolysis (TEN: also known as Lyell&#39;s syndrome), Stevens Johnson syndrome (SJS) and drug reaction with eosinophilia and systemic symptoms (DRESS), which could be life-threatening or fatal, have been reported with levofloxacin (see section 4.8). At the time of prescription, patients should be advised of the signs and symptoms of severe skin reactions, and be closely monitored. If signs and symptoms suggestive of these reactions appear, levofloxacin should be discontinued immediately and an alternative treatment should be considered. If the patient has developed a serious reaction such as SJS, TEN or DRESS with the use of levofloxacin, treatment with levofloxacin must not be restarted in this patient at any time.</p><p>Dysglycaemia</p><p>As with all quinolones, disturbances in blood glucose, including both hypoglycaemia and hyperglycaemia have been reported, usually in diabetic patients receiving concomitant treatment with an oral hypoglycaemic agent (e.g., glibenclamide) or with insulin. Cases of hypoglycaemic coma have been reported. In diabetic patients, careful monitoring of blood glucose is recommended (see section 4.8).</p><p>Evox tablets treatment should be stopped immediately if a patient reports blood glucose disturbance and alternative nonfluoroquinolone antibacterial therapy should be considered.</p><p>Prevention of photosensitisation</p><p>Photosensitisation has been reported with levofloxacin (see section 4.8). It is recommended that patients should not expose themselves unnecessarily to strong sunlight or to artificial UV rays (e.g. sunray lamp, solarium), during treatment and for 48 hours following treatment discontinuation in order to prevent photosensitisation.</p><p>Patients treated with Vitamin K antagonists</p><p>Due to possible increase in coagulation tests (PT/INR) and/or bleeding in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin), coagulation tests should be monitored when these drugs are given concomitantly (see section 4.5).</p><p>Psychotic reactions</p><p>Psychotic reactions have been reported in patients receiving quinolones, including levofloxacin. In very rare cases these have progressed to suicidal thoughts and self-endangering behaviour- sometimes after only a single dose of levofloxacin (see section 4.8). In the event that the patient develops these reactions, levofloxacin should be discontinued and appropriate measures instituted. Caution is recommended if levofloxacin is to be used in psychotic patients or in patients with history of psychiatric disease.</p><p>QT interval prolongation</p><p>Caution should be taken when using fluoroquinolones, including levofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:</p><p>- congenital long QT syndrome</p><p>- concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics).</p><p>- uncorrected electrolyte imbalance (e.g. hypokalemia, hypomagnesemia)</p><p>- cardiac disease (e.g. heart failure, myocardial infarction, bradycardia)</p><p>Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, caution should be taken when using fluoroquinolones, including levofloxacin, in these populations. (See sections 4.2 Elderly, 4.5, 4.8, and 4.9).</p><p>Peripheral neuropathy</p><p>Cases of sensory or sensorimotor polyneuropathy resulting in paraesthesia, hypaesthesia, dysesthesia, or weakness have been reported in patients receiving quinolones and fluoroquinolones. Patients under treatment with levofloxacin should be advised to inform their doctor prior to continuing treatment if symptoms of neuropathy such as pain, burning, tingling, numbness, or weakness develop in order to prevent the development of potentially irreversible condition. (see section 4.8)</p><p>Hepatobiliary disorders</p><p>Cases of hepatic necrosis up to fatal hepatic failure have been reported with levofloxacin, primarily in patients with severe underlying diseases, e.g. sepsis (see section 4.8). Patients should be advised to stop treatment and contact their doctor if signs and symptoms of hepatic disease develop such as anorexia, jaundice, dark urine, pruritus or tender abdomen.</p><p>Exacerbation of myasthenia gravis</p><p>Fluoroquinolones, including levofloxacin, have neuromuscular blocking activity and may exacerbate muscle weakness in patients with myasthenia gravis. Postmarketing serious adverse reactions, including deaths and the requirement for respiratory support, have been associated with fluoroquinolone use in patients with myasthenia gravis. Levofloxacin is not recommended in patients with a known history of myasthenia gravis.</p><p>Vision disorders</p><p>If vision becomes impaired or any effects on the eyes are experienced, an eye specialist should be consulted immediately (see sections 4.7 and 4.8).</p><p>Superinfection</p><p>The use of levofloxacin, especially if prolonged, may result in overgrowth of non-susceptible organisms. If superinfection occurs during therapy, appropriate measures should be taken.</p><p>Interference with laboratory tests</p><p>In patients treated with levofloxacin, determination of opiates in urine may give false-positive results. It may be necessary to confirm positive opiate screens by more specific method.</p><p>Levofloxacin may inhibit the growth of Mucobacterium tuberculosis and, therefore, may give false-negative results in the bacteriological diagnosis of tuberculosis</p><p>Aortic aneurysm and dissection, and heart valve regurgitation/incompetence</p><p>Epidemiologic studies report an increased risk of aortic aneurysm and dissection, particularly in elderly patients, and of aortic and mitral valve regurgitation after intake of fluoroquinolones.</p><p>Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.8).</p><p>Therefore, fluoroquinolones should only be used after careful benefit-risk assessment and after consideration of other therapeutic options in patients with positive family history of aneurysm disease or congenital heart valve disease, or in patients diagnosed with pre-existing aortic aneurysm and/or dissection or heart valve disease, or in presence of other risk factors or conditions predisposing</p><p>&bull; for both aortic aneurysm and dissection and heart valve regurgitation/incompetence (e.g. connective tissue disorders such as Marfan syndrome or Ehlers-Danlos syndrome, Turner syndrome, Behcet&rsquo;s disease, hypertension, rheumatoid arthritis) or additionally.</p><p>&bull; for aortic aneurysm and dissection (e.g. vascular disorders such as Takayasu arteritis or giant cell arteritis, or known atherosclerosis, or Sjogren&rsquo;s syndrome) or additionally</p><p>&bull; for heart valve regurgitation/incompetence (e.g. infective endocarditis).</p><p>The risk of aortic aneurysm and dissection, and their rupture may also be increased in patients treated concurrently with systemic corticosteroids. In case of sudden abdominal, chest or back pain, patients should be advised to immediately consult a physician in an emergency department.</p><p>Patients should be advised to seek immediate medical attention in case of acute dyspnoea, new onset of heart palpitations, or development of oedema of the abdomen or lower extremities.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td>&nbsp;</td><td><p>Effect of other medicinal products on Evox</p><p>Iron salts, zinc salts, magnesium- or aluminium-containing antacids, didanosine</p><p>Levofloxacin absorption is significantly reduced when iron salts, or magnesium- or aluminium-containing antacids, or didanosine (only didanosine formulations with aluminium or magnesium containing buffering agents) are administered concomitantly with Evox tablets. Concurrent administration of fluoroquinolones with multi-vitamins containing zinc appears to reduce their oral absorption. It is recommended that preparations containing divalent or trivalent cations such as iron salts, zinc salts or magnesium- or aluminium-containing antacids, or didanosine (only didanosine formulations with aluminium or magnesium containing buffering agents) should not be taken 2 hours before or after Evox tablet administration (see section 4.2). Calcium salts have a minimal effect on the oral absorption of levofloxacin.</p><p>Sucralfate</p><p>The bioavailability of &nbsp;Evox tablets is significantly reduced when administered together with sucralfate. If the patient is to receive both sucralfate and Evox, it is best to administer sucralfate 2 hours after the Evox tablet administration (see section 4.2).</p><p>Theophylline, fenbufen or similar non-steroidal anti-inflammatory drugs</p><p>No pharmacokinetic interactions of levofloxacin were found with theophylline in a clinical study. However a pronounced lowering of the cerebral seizure threshold may occur when quinolones are given concurrently with theophylline, non-steroidal anti-inflammatory drugs, or other agents which lower the seizure threshold.</p><p>Levofloxacin concentrations were about 13% higher in the presence of fenbufen than when administered alone.</p><p>Probenecid and cimetidine</p><p>Probenecid and cimetidine had a statistically significant effect on the elimination of levofloxacin. The renal clearance of levofloxacin was reduced by cimetidine (24%) and probenecid (34%). This is because both drugs are capable of blocking the renal tubular secretion of levofloxacin. However, at the tested doses in the study, the statistically significant kinetic differences are unlikely to be of clinical relevance.</p><p>Caution should be exercised when levofloxacin is coadministered with drugs that affect the tubular renal secretion such as probenecid and cimetidine, especially in renally impaired patients.</p><p>Other relevant information</p><p>Clinical pharmacology studies have shown that the pharmacokinetics of levofloxacin were not affected to any clinically relevant extent when levofloxacin was administered together with the following drugs: calcium carbonate, digoxin, glibenclamide, ranitidine.</p><p>Effect of Evox on other medicinal products</p><p>Ciclosporin</p><p>The half-life of ciclosporin was increased by 33% when coadministered with levofloxacin.</p><p>Vitamin K antagonists</p><p>Increased coagulation tests (PT/INR) and/or bleeding, which may be severe, have been reported in patients treated with levofloxacin in combination with a vitamin K antagonist (e.g. warfarin). Coagulation tests, therefore, should be monitored in patients treated with vitamin K antagonists (see section 4.4).</p><p>Drugs known to prolong QT interval</p><p>Levofloxacin, like other fluoroquinolones, should be used with caution in patients receiving drugs known to prolong the QT interval (e.g. Class IA and III antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics) (see section 4.4 QT interval prolongation).</p><p>Other relevant information</p><p>In a pharmacokinetic interaction study, levofloxacin did not affect the pharmacokinetics of theophylline (which is a probe substrate for CYP1A2), indicating that levofloxacin is not a CYP1A2 inhibitor.</p><p>Other forms of interactions</p><p>Food</p><p>There is no clinically relevant interaction with food. Evox tablets may therefore be administered regardless of food intake</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy</p><p>There are limited amount of data from the use of levofloxacin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). However in the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in pregnant women (see sections 4.3 and 5.3).</p><p>Breast-feeding</p><p>Evox is contraindicated in breast-feeding women. There is insufficient information on the excretion of levofloxacin in human milk; however, other fluoroquinolones are excreted in breast milk. In the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in breast-feeding women (see sections 4.3 and 5.3).</p><p>Fertility</p><p>Levofloxacin caused no impairment of fertility or reproductive performance in rats</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Some undesirable effects (e.g. dizziness/vertigo, drowsiness, visual disturbances) may impair the patient&#39;s ability to concentrate and react, and therefore may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The information given below is based on data from clinical studies in more than 8300 patients and on extensive post marketing experience.</p><p>Frequencies are defined using the following convention: very common (&ge;1/10), common (&ge;1/100, &lt;1/10), uncommon (&ge;1/1000, &lt;1/100), rare (&ge;1/10000, &lt;1/1000), very rare (&lt;1/10000), not known (cannot be estimated from the available data).</p><p>Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>System organ class</p></td><td style="vertical-align:top"><p>Common</p><p>(&ge;1/100 to &lt;1/10 )</p></td><td style="vertical-align:top"><p>Uncommon</p><p>(&ge;1/1,000 to &lt;1/100)</p></td><td style="vertical-align:top"><p>Rare</p><p>&nbsp;(&ge;1/10,000 to &lt;1/1,000)</p></td><td style="vertical-align:top"><p>Not known (cannot be estimated from available data)</p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Fungal infection including Candida infection</p><p>Pathogen resistance</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Leukopenia</p><p>Eosinophilia</p></td><td style="vertical-align:top"><p>Thrombocytopenia</p><p>Neutropenia</p></td><td style="vertical-align:top"><p>Pancytopenia</p><p>Agranulocytosis</p><p>Haemolytic anaemia</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Angioedema</p><p>Hypersensitivity (see section 4.4)</p></td><td style="vertical-align:top"><p>Anaphylactic shock<sup>a</sup></p><p>Anaphylactoid shock<sup>a</sup> (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>Hypoglycaemia particularly in diabetic patients (see section 4.4)</p></td><td style="vertical-align:top"><p>Hyperglycaemia &nbsp;(see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders*</p></td><td style="vertical-align:top"><p>Insomnia</p></td><td style="vertical-align:top"><p>Anxiety</p><p>Confusional state</p><p>Nervousness</p></td><td style="vertical-align:top"><p>Psychotic reactions (with e.g. hallucination, paranoia)</p><p>Depression</p><p>Agitation</p><p>Abnormal dreams</p><p>Nightmares</p></td><td style="vertical-align:top"><p>Psychotic disorders with self-endangering behaviour including suicidal ideation or suicide attempt (see section 4.4)</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders*</p></td><td style="vertical-align:top"><p>Headache</p><p>Dizziness</p></td><td style="vertical-align:top"><p>Somnolence</p><p>Tremor</p><p>Dysgeusia</p></td><td style="vertical-align:top"><p>Convulsion (see sections 4.3 and 4.4) Paraesthesia, Memory impairment</p></td><td style="vertical-align:top"><p>Peripheral sensory neuropathy (see section 4.4)</p><p>Peripheral sensory motor neuropathy (see section 4.4)</p><p>Parosmia including anosmia</p><p>Dyskinesia</p><p>Extrapyramidal disorder</p><p>Ageusia</p><p>Syncope</p><p>Benign intracranial hypertension</p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Visual disturbances such as blurred vision (see section 4.4)</p></td><td style="vertical-align:top"><p>Transient vision loss (see section 4.4)</p><p>uveitis</p></td></tr><tr><td style="vertical-align:top"><p>Ear and Labyrinth disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top"><p>Hearing loss</p><p>Hearing impaired</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders**</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Tachycardia</p><p>Palpitation</p></td><td style="vertical-align:top"><p>Ventricular tachycardia, which may result in cardiac arrest</p><p>Ventricular arrhythmia, and torsade de pointes (reported predominantly in patients with risk factors of QT prolongation), Electrocardiogram QT prolonged (see sections 4.4 and 4.9)</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders**</p></td><td style="vertical-align:top"><p>Applies to iv form only:</p><p>Phlebitis</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Bronchospasm, Pneumonitis allergic</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Diarrhoea</p><p>Vomiting</p><p>Nausea</p></td><td style="vertical-align:top"><p>Abdominal pain</p><p>Dyspepsia</p><p>Flatulence</p><p>Constipation</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Diarrhoea &ndash;haemorrhagic which in very rare cases may be indicative of enterocolitis, including pseudomembranous colitis (see section 4.4)</p><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Hepatic enzyme increased (ALT/AST, alkaline phosphatase, GGT)</p></td><td style="vertical-align:top"><p>Blood bilirubin increased</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Jaundice and severe liver injury, including cases with fatal acute liver failure, primarily in patients with severe underlying diseases (see section 4.4)</p><p>Hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders<sup>b</sup></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rash</p><p>Pruritus</p><p>Urticaria</p><p>Hyperhidrosis</p></td><td style="vertical-align:top"><p>Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) (see section 4.4), Fixed drug eruption</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p><p>Stevens-Johnson syndrome</p><p>Erythema multiforme</p><p>Photosensitivity reaction (see section 4.4)</p><p>Leukocytoclastic vasculitis</p><p>Stomatitis</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders*</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Arthralgia</p><p>Myalgia</p></td><td style="vertical-align:top"><p>Tendon disorder (see sections 4.3 and 4.4) including tendinitis (e.g. Achilles tendon)</p><p>Muscular weakness which may be of importance in patients with myasthenia gravis (see section 4.4)</p></td><td style="vertical-align:top"><p>Rhabdomyolysis</p><p>Tendon rupture (e.g. Achilles tendon) (see sections 4.3 and 4.4)</p><p>Ligament rupture</p><p>Muscle rupture</p><p>Arthritis</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Renal failure acute (e.g. due to interstitial nephritis)</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Applies to iv form only:</p><p>Infusion site reaction (pain, reddening)</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Pyrexia</p></td><td style="vertical-align:top"><p>Pain (including pain in back, chest, and extremities)</p></td></tr></tbody></table><p><sup>a</sup> Anaphylactic and anaphylactoid reactions may sometimes occur even after the first dose</p><p><sup>b</sup> Mucocutaneous reactions may sometimes occur even after the first dose</p><p>Other undesirable effects which have been associated with fluoroquinolone administration include:</p><p>&bull; attacks of porphyria in patients with porphyria.</p><p>* Very rare cases of prolonged (up to months or years), disabling and potentially irreversible serious drug reactions affecting several, sometimes multiple, system organ classes and senses (including reactions such as tendonitis, tendon rupture, arthralgia, pain in extremities, gait disturbance, neuropathies associated with paraesthesia, depression, fatigue, memory impairment, sleep disorders, and impairment of hearing, vision, taste and smell) have been reported in association with the use of quinolones and fluoroquinolones in some cases irrespective of pre-existing risk factors (see Section 4.4).</p><p>** Cases of aortic aneurysm and dissection, sometimes complicated by rupture (including fatal ones), and of regurgitation/incompetence of any of the heart valves have been reported in patients receiving fluoroquinolones (see section 4.4).</p><p>Reporting of suspected adverse reactions</p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>To reports any side effect(s):</p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p>&nbsp; Website: https://ade.sfda.gov.sa</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>According to toxicity studies in animals or clinical pharmacology studies performed with supra-therapeutic doses, the most important signs to be expected following acute overdose of Evox tablets are central nervous system symptoms such as confusion, dizziness, impairment of consciousness, and convulsive seizures, increases in QT interval as well as gastro-intestinal reactions such as nausea and mucosal erosions.</p><p>CNS effects including confusional state, convulsion, hallucination, and tremor have been observed in post marketing experience.</p><p>In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation.</p><p>Antacids may be used for protection of gastric mucosa. Haemodialysis, including peritoneal dialysis and CAPD, are not effective in removing levofloxacin from the body. No specific antidote exists</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0" style="width:100%"><tbody><tr><td><p>Pharmacotherapeutic group: quinolone antibacterials, fluoroquinolones</p><p>ATC code: J01MA12</p><p>Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class and is the S (-) enantiomer of the racemic active substance ofloxacin.</p><p>Mechanism of action</p><p>As a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA-DNA-gyrase complex and topoisomerase IV.</p><p>PK/PD relationship</p><p>The degree of the bactericidal activity of levofloxacin depends on the ratio of the maximum concentration in serum (Cmax) or the area under the curve (AUC) and the minimal inhibitory concentration (MIC).</p><p>Mechanism of resistance</p><p>Resistance to levofloxacin is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV. Other resistance mechanisms such as permeation barriers (common in Pseudomonas aeruginosa) and efflux mechanisms may also affect susceptibility to levofloxacin.</p><p>Cross-resistance between levofloxacin and other fluoroquinolones is observed. Due to the mechanism of action, there is generally no cross-resistance between levofloxacin and other classes of antibacterial agents.</p><p>Breakpoints</p><p>The EUCAST recommended MIC breakpoints for levofloxacin, separating susceptible from intermediately susceptible organisms and intermediately susceptible from resistant organisms are presented in the below table for MIC testing (mg/l).</p><p>EUCAST clinical MIC breakpoints for levofloxacin (version 10.0, 2020-01- 01):</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Pathogen</p></td><td style="vertical-align:top"><p>Susceptible</p></td><td style="vertical-align:top"><p>Resistant</p></td></tr><tr><td style="vertical-align:top"><p>Enterobacteriacae</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p></td><td style="vertical-align:top"><p>&gt;1 mg/l</p></td></tr><tr><td style="vertical-align:top"><p>Pseudomonas spp.</p></td><td style="vertical-align:top"><p>&le; 0.001 mg/l</p></td><td style="vertical-align:top"><p>&gt;1 mg/l</p></td></tr><tr><td style="vertical-align:top"><p>Acinetobacter spp.</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p></td><td style="vertical-align:top"><p>&gt;1 mg/l</p></td></tr><tr><td style="vertical-align:top"><p>Staphylococcus spp.</p><p>Coagulase-negative staphylococci</p></td><td style="vertical-align:top"><p>&le; 0.001 mg/l</p></td><td style="vertical-align:top"><p>&gt;1 mg/l</p></td></tr><tr><td style="vertical-align:top"><p>Enterococcus spp.<sup>1</sup></p></td><td style="vertical-align:top"><p>&le; 4 mg/l</p></td><td style="vertical-align:top"><p>&gt; 4 mg/l</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus pneumoniae</p></td><td style="vertical-align:top"><p>&le; 0.001 mg/l</p></td><td style="vertical-align:top"><p>&gt;2 mg/l</p></td></tr><tr><td style="vertical-align:top"><p>Streptococcus groups A, B, C and G</p></td><td style="vertical-align:top"><p>&le; 0.001 mg/l</p></td><td style="vertical-align:top"><p>&gt;2 mg/l</p></td></tr><tr><td style="vertical-align:top"><p>Haemophilus influenzae</p></td><td style="vertical-align:top"><p>&le; 0.06 mg/l</p></td><td style="vertical-align:top"><p>&gt; 0.06 mg/l</p></td></tr><tr><td style="vertical-align:top"><p>Moraxella catarrhalis</p></td><td style="vertical-align:top"><p>&le; 0.125 mg/l</p></td><td style="vertical-align:top"><p>&gt; 0.125 mg/l</p></td></tr><tr><td style="vertical-align:top"><p>Helicobacter pylori</p></td><td style="vertical-align:top"><p>&le;1 mg/l</p></td><td style="vertical-align:top"><p>&gt;1 mg/l</p></td></tr><tr><td style="vertical-align:top"><p>Aerococcus sanguinicola and urinae<sup>2</sup></p></td><td style="vertical-align:top"><p>&le;2 mg/l</p></td><td style="vertical-align:top"><p>&gt;2 mg/l</p></td></tr><tr><td style="vertical-align:top"><p>Aeromonas spp</p></td><td style="vertical-align:top"><p>&le;0.5 mg/l</p></td><td style="vertical-align:top"><p>&gt;1 mg/l</p></td></tr><tr><td style="vertical-align:top"><p>PK/PD (Non-species related) breakpoints</p></td><td style="vertical-align:top"><p>&le; 0.5 mg/l</p></td><td style="vertical-align:top"><p>&gt;1 mg/l</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p>1: uncomplicated urinary tract infections only</p><p>2: Susceptibility can be inferred from ciprofloxacin susceptibility.</p></td></tr></tbody></table><p>The prevalence of resistance may vary geographically and with time for selected species and local information on resistance is desirable, particularly when treating severe infections. As necessary, expert advice should be sought when the local prevalence of resistance is such that the utility of the agent in at least some types of infections is questionable.</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong><u>Commonly susceptible species </u></strong></p><p><strong><u>Aerobic Gram-positive bacteria</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>Bacillus anthracis</p><p>Staphylococcus aureus methicillin-susceptible</p><p>Staphylococcus saprophyticus</p><p>Streptococci, group C and G</p><p>Streptococcus agalactiae</p><p>Streptococcus pneumoniae</p><p>Streptococcus pyogenes</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Aerobic Gram- negative bacteria </u></strong></p><p>Eikenella corrodens</p><p>Haemophilus influenzae</p><p>Haemophilus para-influenzae</p><p>Klebsiella oxytoca</p><p>Moraxella catarrhalis</p><p>Pasteurella multocida</p><p>Proteus vulgaris</p><p>Providencia rettgeri</p><p><strong><u>Anaerobic bacteria </u></strong></p><p>Peptostreptococcus</p><p><strong><u>Other </u></strong></p><p>Chlamydophila pneumoniae</p><p>Chlamydophila psittaci</p><p>Chlamydia trachomatis</p><p>Legionella pneumophila</p><p>Mycoplasma pneumoniae</p><p>Mycoplasma hominis</p><p>Ureaplasma urealyticum</p></td></tr><tr><td style="vertical-align:top"><p><strong><u>Species for which acquired resistance may be a problem </u></strong></p><p><strong><u>Aerobic Gram-positive bacteria </u></strong></p><p>Enterococcus faecalis</p><p>Staphylococcus aureus methicillin-resistant#</p><p>Coagulase negative Staphylococcus spp</p><p><strong><u>Aerobic Gram- negative bacteria </u></strong></p><p>Acinetobacter baumannii</p><p>Citrobacter freundii</p><p>Enterobacter aerogenes</p><p>Enterobacter cloacae</p><p>Escherichia coli</p><p>Klebsiella pneumoniae</p><p>Morganella morganii</p><p>Proteus mirabilis</p><p>Providencia stuartii</p><p>Pseudomonas aeruginosa</p><p>Serratia marcescens</p><p><strong><u>Anaerobic bacteria </u></strong></p><p>Bacteroides fragilis</p><p><strong><u>Inherently Resistant Strains </u></strong></p><p><strong><u>Aerobic Gram-positive bacteria </u></strong></p><p>Enterococcus faecium</p></td></tr></tbody></table><p># Methicillin-resistant S. aureus are very likely to possess co-resistance to fluoroquinolones, including levofloxacin.</p></td><td>&nbsp;</td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Orally administered levofloxacin is rapidly and almost completely absorbed with peak plasma concentrations being obtained within 1 - 2 h. The absolute bioavailability is 99 - 100 %.</p><p>Food has little effect on the absorption of levofloxacin.</p><p>Steady state conditions are reached within 48 hours following a 500 mg once or twice daily dosage regimen.</p><p><u>Distribution</u></p><p>Approximately 30 - 40 % of levofloxacin is bound to serum protein.</p><p>The mean volume of distribution of levofloxacin is approximately 100 l after single and repeated 500 mg doses, indicating widespread distribution into body tissues.</p><p><u>Penetration into tissues and body fluids:</u></p><p>Levofloxacin has been shown to penetrate into bronchial mucosa, epithelial lining fluid, alveolar macrophages, lung tissue, skin (blister fluid), prostatic tissue and urine. However, levofloxacin has poor penetration into cerebro-spinal fluid.</p><p><u>Biotransformation</u></p><p>Levofloxacin is metabolised to a very small extent, the metabolites being desmethyl-levofloxacin and levofloxacin N-oxide. These metabolites account for &lt;5 % of the dose and are excreted in urine. Levofloxacin is stereochemically stable and does not undergo chiral inversion.</p><p><u>Elimination</u></p><p>Following oral and intravenous administration of levofloxacin, it is eliminated relatively slowly from the plasma (t&frac12; : 6 - 8 h). Excretion is primarily by the renal route (&gt;85 % of the administered dose).</p><p>The mean apparent total body clearance of levofloxacin following a 500 mg single dose was 175 +/-29.2 ml/min.</p><p>There are no major differences in the pharmacokinetics of levofloxacin following intravenous and oral administration, suggesting that the oral and intravenous routes are interchangeable.</p><p><u>Linearity </u></p><p>Levofloxacin obeys linear pharmacokinetics over a range of 50 to 1000 mg.</p><p><u>Special populations</u></p><p><em>Subjects with renal insufficiency</em></p><p>The pharmacokinetics of levofloxacin are affected by renal impairment. With decreasing renal function renal elimination and clearance are decreased, and elimination half-lives increased as shown in the table below:</p><p>Pharmacokinetics in renal insufficiency following single oral 500 mg dose</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p>Clcr [ml/min]</p></td><td style="vertical-align:top"><p>&lt; 20</p></td><td style="vertical-align:top"><p>20 - 49</p></td><td style="vertical-align:top"><p>50 - 80</p></td></tr><tr><td style="vertical-align:top"><p>ClR [ml/min]</p></td><td style="vertical-align:top"><p>13</p></td><td style="vertical-align:top"><p>26</p></td><td style="vertical-align:top"><p>57</p></td></tr><tr><td style="vertical-align:top"><p>t1/2 [h]</p></td><td style="vertical-align:top"><p>35</p></td><td style="vertical-align:top"><p>27</p></td><td style="vertical-align:top"><p>9</p></td></tr></tbody></table><p><em>&nbsp;</em><em>Elderly subjects</em></p><p>There are no significant differences in levofloxacin pharmacokinetics between young and elderly subjects, except those associated with differences in creatinine clearance.</p><p><em>Gender differences</em></p><p>Separate analysis for male and female subjects showed small to marginal gender differences in levofloxacin pharmacokinetics. There is no evidence that these gender differences are of clinical relevance</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential and toxicity to reproduction and development.</p><p>Levofloxacin caused no impairment of fertility or reproductive performance in rats and its only effect on fetuses was delayed maturation as a result of maternal toxicity.</p><p>Levofloxacin did not induce gene mutations in bacterial or mammalian cells but did induce chromosome aberrations in Chinese hamster lung cells in vitro. These effects can be attributed to inhibition of topoisomerase II. In vivo tests (micronucleus, sister chromatid exchange, unscheduled DNA synthesis, dominant lethal tests) did not show any genotoxic potential.</p><p>Studies in the mouse showed levofloxacin to have phototoxic activity only at very high doses. Levofloxacin did not show any genotoxic potential in a photomutagenicity assay, and it reduced tumour development in a photocarcinogenity study.</p><p>In common with other fluoroquinolones, levofloxacin showed effects on cartilage (blistering and cavities) in rats and dogs. These findings were more marked in young animals.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prossolve 90, Povidone K-30, Crospovidone, Colloidal silicon dioxide, Talc, Magnesium Stearate, Sepifilm 033 (HPMC polymer), Sepisperse yellow 3050 (HPMC polymer and Yellow iron oxide) &amp; Titanium dioxide (only in <strong>Evox </strong>500 &amp; 750)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicabl</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>One Aluminium / Aluminium blisters contains 7 or 14 Tablets packed in a printed cardboard case with a folded package insert..</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jordan Sweden Medical and Sterilization Company (JOSWE-medical)
P.O. Box 851831 Amman 11185 Jordan 
E-mail: info@joswe.com
Head office: Sweifyeh.
Tel: +962 6 5859765 - + 962 6 5812748
Fax: +962 6 5814526
Fax: +962 6 5728326

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April, 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>